Unilateral intraputamenal glial cell line–derived neurotrophic factor in patients with Parkinson disease: Response to 1 year of treatment and 1 year of withdrawal
Abstract
OBJECT: Glial cell line-derived neurotrophic factor (GDNF) infused unilaterally into the putamen for 6 months has been previously shown to improve significantly motor functions and quality of life measures in 10 patients with Parkinson disease (PD) in a Phase I trial. In the present study the authors report the safety and efficacy of continuous treatment for a minimum of 1 year. After the trial was halted by the drug sponsor, the patients were monitored for an additional 1 year during which the effects of drug withdrawal were evaluated. METHODS: During the extended study period, patients received a 30-microg/day unilateral intraputamenal infusion of GDNF at a basal infusion rate supplemented with pulsed boluses every 6 hours at a convection-enhanced delivery rate to increase tissue penetration of the protein. When the study was stopped, the delivery system was reprogrammed to deliver sterile saline at the basal infusion rate of 2 microl/hour. The Unified Parkinson's Disease Rating Scale (UPDRS) total scores after 1 year of therapy were improved by 42 and 38% in the off- and on-medication states; the motor UPDRS scores were also improved 45 and 39%, respectively. Benefits from treatment were lost by 9 to 12 months after the cessation of GDNF infusion. The UPDRS scores returned to their baseline and the patients required higher levels of conventional antiparkinsonian drugs to treat symptoms. After 11 months of treatment, the delivery system had to be removed in one patient because of risk of infection. Seven patients developed antibodies to GDNF but without evident clinical sequelae. There was no evidence for GDNF-induced cerebellar toxicity, as evaluated by magnetic resonance imaging and clinical testing. CONCLUSIONS: The unilateral administration of GDNF results in significant, sustained bilateral benefits in patients with PD. These improvements are lost within 9 months of drug withdrawal. Safety concerns with GDNF therapy can be closely monitored and managed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical trials using neurotrophins in the treatment of Parkinson's disease are rather limited to GDNF administration instead of BDNF.
“Clinical trials using NTs in the treatment of PD are rather limited to GDNF administration instead of BDNF.”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [108]
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526 · see citing works
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290 · see citing works
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079 · see citing works
Lang, A. E., Gill, S., Patel, N., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G. R., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 987 · see citing works
Functional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955 · see citing works
Self-citationRandomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C., Jankovic, J. J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M. A., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 816 · see citing works
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654 · see citing works
Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R. J., & Young, B. A. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 474 · see citing works
Self-citationPatel, N. K., Bunnage, M., Plaha, P., Svendsen, C. N., Heywood, P. G., & Gill, S. S. (2005) · Annals of Neurology · doi:10.1002/ana.20374 · Cited by 384 · see citing works
Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain
Love, S., Plaha, P., Patel, N. K., Hotton, G. R., Brooks, D. J., & Gill, S. S. (2005) · Nature Medicine · doi:10.1038/nm0705-703 · Cited by 285 · see citing works
Point source concentration of GDNF may explain failure of phase II clinical trial
Salvatore, M. F., Ai, Y., FISCHER, B., ZHANG, A., Grondin, R., Zhang, Z., Gerhardt, G. A., & Gash, D. M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.015 · Cited by 261 · see citing works
Self-citationFrancis, G., Rice, G. P., & Alsop, J. C. (2005) · Neurology · doi:10.1212/01.wnl.0000171748.48188.5b · Cited by 176 · see citing works
Crossroads in GDNF therapy for Parkinson's disease
Sherer, T., Fiske, B. K., Svendsen, C. N., Lang, A. E., & Langston, J. W. (2006) · Movement Disorders · doi:10.1002/mds.20861 · Cited by 172 · see citing works
Wilms, H., Sievers, J., & Deuschl, G. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 171 · see citing works
Trophic factor distribution predicts functional recovery in parkinsonian monkeys
Gash, D. M., Zhang, Z., Ai, Y., Grondin, R., Coffey, R. J., & Gerhardt, G. A. (2005) · Annals of Neurology · doi:10.1002/ana.20549 · Cited by 97 · see citing works
Self-citationSajadi, A., Bensadoun, J., Schneider, B. L., Bianco, C. L., & Aebischer, P. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.10.006 · Cited by 79 · see citing works
Neutralizing antibodies and efficacy of interferon β-1a
Kappos, L., Clanet, M., Sandberg-wollheim, M., Radue, E., Hartung, H., Hohlfeld, R., Xu, J., Bennett, D., Sandrock, A., & Goelz, S. (2005) · Neurology · doi:10.1212/01.wnl.0000171747.59767.5c · Cited by 65 · see citing works
Ericson, C., Georgievska, B., & Lundberg, C. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04503.x · Cited by 63 · see citing works
GDNF in Parkinson disease: An object lesson in the tyranny of type II
Hutchinson, M., Gurney, S., & Newson, R. B. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.06.015 · Cited by 34 · see citing works
Chebrolu, H., Slevin, J. T., GASH, D., et al. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.021 · Cited by 30 · see citing works
Self-citationPeck, P. (2005) · Neurology Today · doi:10.1097/00132985-200504000-00004 · Cited by 15 · see citing works
WHY THE FIELD NEEDS A NEUROCRITICAL CARE ORGANIZATION
Sung, G. Y., Smith, W. S., Hemphill, J. C., et al. (2003) · Neurology Today · doi:10.1097/00132985-200303000-00004 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820 · see citing works
Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease
Mattson, M. P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.005 · Cited by 640 · see citing works
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504 · see citing works
New approaches for brain repair-from rescue to reprogramming
Barker, R. A., Götz, M., & Parmar, M. (2018) · Nature · doi:10.1038/s41586-018-0087-1 · Cited by 214 · see citing works
Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm
Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., & Saragovi, H. U. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.004 · Cited by 54 · see citing works
Controlled dissemination of AAV vectors in the primate brain
Varenika, V., Kells, A. P., Valles, F., Hadaczek, P., Forsayeth, J., & Bankiewicz, K. S. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17511-8 · Cited by 33 · see citing works
- Authors
- Slevin, J. T., Gash, D. M., Smith, C. D., Gerhardt, G. A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R., & Young, A. B.
- Affiliations
- Veterans Health Administration (US)
- Anatomy and Neurobiology,
- University of Kentucky (US)
- Departments of Neurology,
- Statistics and Public Health, and
- Neurosurgery;
- Venue
- Journal of neurosurgery
- Published
- 2007-04
- Volume
- 106
- Issue
- 4
- Pages
- 614-620
- ISSN
- 0022-3085 (ISSN-L)
- OpenAlex
- W2145568285
- Cited by
- 173
- References
- 22
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 9 · 2022: 3 · 2021: 7 · 2020: 12 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 4 · 2015: 6 · 2014: 10 · 2013: 14 · 2012: 14
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of neurosurgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- glial cell line-derived neurotrophic factor, Parkinson's disease, convection-enhanced delivery, long-term treatment efficacy, motor function, cerebellar toxicity, treatment safety
- MeSH terms
- Aged, Antiparkinson Agents, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Motor Activity, Parkinson Disease, Putamen, Infusion Pumps, Implantable, Treatment Outcome, Withholding Treatment, Glial Cell Line-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
